As a leading CRO of antibody generation and development, Creative Biolabs offers application-specific antibody development services to global clients. With experienced scientists and advanced technology, we have established a series of high-quality in vitro diagnostic (IVD) antibody development services against biomarkers of different diseases. Here, we introduce our IVD antibody development services for brain natriuretic peptide (BNP).

Brain Natriuretic Peptide (BNP)

Brain natriuretic peptide (BNP) is named as such because it was originally identified in extracts of pig brain. It is a hormone secreted by ventricular myocytes that responds to stretching caused by an increase in ventricular blood volume. The 32-amino acid polypeptide BNP is secreted attached to a 76-amino acid N-terminal fragment in the prohormone called NT-proBNP (BNPT), which is biologically inactive. Once released, BNP binds to and activates the atrial natriuretic factor receptor NPRA in a manner similar to ANP, and to a lesser extent NPRB, but with a 10-fold lower affinity. The biological half-life of BNP, however, is twice as long as that of ANP, and that of NT-proBNP is even longer, making these peptides better targets than ANP for diagnostic blood testing. The physiological effects of BNP are similar to those of ANP, including decrease in systemic vascular resistance, central venous pressure and increasing natriuresis.

Normal physiology of natriuretic peptides. Fig.1 Normal physiology of natriuretic peptides. (McFarlane, 2003)

BNP Marker of Sepsis Infections

BNP is a diagnostic marker for left ventricular dysfunction. Sepsis and septic shock are increasing in incidence and mortality. Myocardial dysfunction is often accompanied by severe sepsis and septic shock. Although previously described as a preterminal event, ventricular dysfunction with reduced ejection fraction and biventricular dilatation is present in most patients with severe sepsis and septic shock. In survivors, this depression in cardiac function is reversible over the course of seven to ten days. Even though some prognostic factors have been identified in patients with sepsis-induced myocardial dysfunction, their measurement often includes costly and cumbersome techniques. Therefore, there is a need for simple, fast, inexpensive and readily available markers to predict mortality in septic shock. Growing evidence supports the hypothesis that BNP could be an early predictor of mortality in septic shock. If proven, the hypothesis would have important clinical and public health implications.

BNP Marker of Heart Failure

HF happens when the heart can't pump enough blood to meet the body's requirements, usually rendered as shortness of breath, leg swelling and excessive tiredness. It has extensively recognized that BNP is a gold standard marker of HF. BNP acts an essential role in the diagnosis, prognosis, and management of acute heart failure (AHF), and it is available clinically to evaluate the severity of HF and risk stratification. However, BNP is extremely specific and function much better as a ‘‘rule out'' test than a ‘‘rule in'' test for AHF, it should be used with clinical signs, symptoms and other investigations.

BNP Marker of Left Ventricular Dysfunction

LVD with subsequent congestive heart failure (CHF) consist of the ultima general pathway for a great number of cardiac disorders. Diagnosing and treating the LVD is a crucial therapeutic goal for patients with cardiac disorders. BNP is released from the cardiac ventricle in response to left ventricular volume expansion. It is a standalone predictor of high left ventricular end-diastolic pressure and a widely recognized marker of systolic LVD. It has been proven that BNP was advanced in patients with LVD, and the current ventricular conditions can be exactly reflected by BNP, because the half-life of that was 20 minutes.

Stages in the course of paediatric ventricular dysfunction. Fig.2 Stages in the course of paediatric ventricular dysfunction. (Lipshultz, 2013)

IVD Antibody Development Services Targeting BNP Marker

IVD antibodies are extensively used for disease screening, prognosis, and therapeutic monitoring. With our versatile IVD platform, Creative Biolabs is proud to develop novel anti-BNP antibodies from scratch to commercial IVD kit. If you are interested in our services, please feel free to contact us for more details.

References

  1. McFarlane, SI., (2003). “Role of the natriuretic peptide system in cardiorenal protection.” Arch Intern Med 163(22): 2696-2704.
  2. Lipshultz, S. E. (2013). “Treatment-related cardiotoxicity in survivors of childhood cancer”. Nature reviews Clinical oncology 10(12), 697-710.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.